HOME >> BIOLOGY >> NEWS
Studies throw light on biomarkers which predict the subsets of patients where gefitinib has the greatest benefit

Note: This press release has been updated since it was originally posted.

PHILADELPHIA The drug gefitinib (Iressa) was approved by the U.S. Food and Drug Administration (FDA) in May 2003 under the agencys accelerated approval program for the treatment of patients with non-small cell lung cancer (NSCLC) who had failed two or more courses of chemotherapy. Consistent with the requirements of accelerated approval, the sponsoring company continued to study the drug to verify the expected clinical benefit. In December 2004, the FDA released a statement notifying the failure of a large clinical trial of gefitinib to show an overall survival advantage compared to placebo in treating patients with lung cancer. In June 2005, FDA issued a new label for gefitinib that limits use to patients with cancer who in the opinion of their treating physician, are currently benefiting, or have previously benefited, from Iressa treatment.

However, oncologists believe that Iressa still holds promise and continue investigating its potential. Several studies presented at the Annual International Conference on Molecular Targets and Cancer Therapeutics coordinated by the American Association for Cancer Research (AACR), the National Cancer Institute (NCI) and the European Organisation for Research and Treatment of Cancer (EORTC) explore the ways in which gefitinib may work on tumors and which patients may benefit the most.

These include:

  • Molecular markers may be the key to ensuring successful treatment with gefitinib.
  • Lung cancer patients with these markers may have a greater chance of survival benefit with gefitinib treatment.
  • Lung cancer patients chance of survival with gefitinib may lie with an inherited genetic contribution in patients with a good disease performance status.

Epidermal Growth Factor (EGFR), K-Ras and B-Raf Mutation Status and Clinical Outcome to Gefitinib (Iressa) in Phase III Place
'"/>

Contact: Warren R. Froelich
froelich@aacr.org
215-440-9300
American Association for Cancer Research
15-Nov-2005


Page: 1 2 3 4 5

Related biology news :

1. Studies to find better ways to preserve human eggs, ovarian tissue under way
2. Studies assess effectiveness of serotonin and nerve stimulants on irritable bowel syndromes
3. The Institute of Ecosystem Studies recognized by the Wildlife Society
4. The Institute of Ecosystem Studies to host an international conference on ecology and urban design
5. Hot flashes -- Studies explore the role of genes, obesity and alcohol
6. Studies force new view on biology of flavonoids
7. Studies of population genetics, evolution are an exercise in bad taste
8. Studies identify DNA regions linked to nicotine dependence
9. Studies at cancer conference show new therapies changing outlook for blood cancer patients
10. Studies find general mechanism of cellular aging
11. Institute of Ecosystem Studies director and scientist honored by the Botanical Society of America

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/21/2020)... ... August 19, 2020 , ... ... and SalivaBio LLC, businesses dedicated to Salivary Bioscience for more than twenty years. ... published book by Springer, " Salivary Bioscience: Foundations of Interdisciplinary Saliva Research and ...
(Date:8/21/2020)... ... August 20, 2020 , ... NDA Partners Chairman ... Operations executive with expertise in clinical trial planning and feasibility, regulatory inspection readiness, ... Consultant. Throughout his career, Mr. Movahhed has helped design and manage oncology, neurology, ...
(Date:8/12/2020)... ... August 12, 2020 , ... Mosio recently announced its ... public health agencies of all sizes. With a focus on tracking symptoms and ... appropriate health care, Mosio helps public health departments automate communications and provide more ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... 29, 2020 , ... Anomet Products has introduced new custom ... use with CRM, neurostimulation, vascular, and related devices. , Anomet Medical Clad ... performance, and cost criteria; especially where solid wire is limited. Typical configurations for ...
(Date:7/31/2020)... ... , ... eSource has long been touted as the solution to high data ... the reasons it did not take off as quickly as people initially expected, and ... moving towards capturing data electronically for clinical trials and then repurposing it for downstream ...
(Date:7/31/2020)... ... July 30, 2020 , ... ... industry, today announced the release of its signature product called Beacon - ... (MSLs) and other field medical professionals. , Beacon helps MSLs streamline ...
(Date:7/18/2020)... ... July 16, 2020 , ... After research model surgery ... of a great surgery is only the beginning of a successful study, while protecting ... , Join Brad Gien, Global Head of Surgery from Envigo in a ...
Breaking Biology Technology:
Cached News: